Patent US4282216A successfully refreshed from Google Patents.
US4282216A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical anti-inflammatory drug therapy
Assignee: Johnson and Johnson
•
Filing: 1979-08-06
•
Granted: 1981-08-04
•
Expires: 1999-08-06
Abstract
Abstract A pharmaceutical composition for topical treatment of cutaneous disorders or disruptions characterized by skin inflammation or hyperproliferative epidermal activity comprises the combination of a topically active anti-inflammatory corticosteroid and a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolone derivatives; the fenamic acid derivatives; the aroyl-substituted pyrroles and the substituted arylacetohydroxamic acids in a pharmaceutically acceptable topical vehicle. Treatment of above cutaneous disorders may also be effected by concurrent therapy using separate applications of corticosteroid and non-steroid.
Inventors
- 👤 D. Thomas Rovee
- 👤 John R. Marvel
- 👤 James A. Mezick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 09:34
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/60; A61K31/56; A61K31/57; A61K31/58; A61K31/618; A61K31/621; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/20; A61K9/00; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
97 words
A method of topical treatment of an inflammatory condition of the skin comprising applying to the affected area a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the tolmetin and ethyl 5-p-chlorobenzoyl-1,4-dimethylpyrrole-2-acetate and, concurrently therewith, a topically active anti-inflammatory corticosteroid, each of said prostaglandin synthetase inhibitor and said corticosteroid being applied in a pharmaceutically acceptable topical vehicle selected from the group consisting of creams, gels, ointments, powders, aerosols and solutions suitable for topical administration, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 2
Independent Claim
97 words
A method of topical treatment of an inflammatory condition of the skin comprising applying to the affected area a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the tolmetin and ethyl 5-p-chlorobenzoyl-1,4-dimethylpyrrole-2-acetate and, concurrently therewith, a topically active anti-inflammatory corticosteroid, each of said prostaglandin synthetase inhibitor and said corticosteroid being applied in a pharmaceutically acceptable topical vehicle selected from the group consisting of creams, gels, ointments, powders, aerosols and solutions suitable for topical administration, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 3
Dependent Claim
29 words
The method of claim 1 wherein said corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 21-butyrate, desonide, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide and betamethasone-17-valerate.
Claim 4
Dependent Claim
11 words
The method of claim 2 wherein said corticosteroid is triamcinolone acetonide.
Claim 5
Dependent Claim
17 words
The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
Claim 6
Dependent Claim
17 words
The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
Claim 7
Dependent Claim
37 words
The method of claim 4 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said topically active corticosteroid comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
Claim 8
Dependent Claim
83 words
A composition for the topical treatment of an inflammatory condition of the skin comprising a pharmaceutically acceptable topical vehicle selected from the group consisting of creams, gels, ointments, powders, aerosols, and solutions suitable for topical administration, said topical vehicle containing a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the tolmetin and ethyl 5-p-chlorobenzoyl-1,4-dimethylpyrrole-2-acetate, and a topically active anti-inflammatory corticosteroid, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 9
Dependent Claim
83 words
A composition for the topical treatment of an inflammatory condition of the skin comprising a pharmaceutically acceptable topical vehicle selected from the group consisting of creams, gels, ointments, powders, aerosols, and solutions suitable for topical administration, said topical vehicle containing a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the tolmetin and ethyl 5-p-chlorobenzoyl-1,4-dimethylpyrrole-2-acetate, and a topically active anti-inflammatory corticosteroid, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 10
Dependent Claim
29 words
The composition of claim 7 wherein said corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 21-butyrate, desonide, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide and betamethasone-17-valerate.
Claim 11
Dependent Claim
11 words
The composition of claim 8 wherein said corticosteroid is triamcinolone acetonide.
Claim 12
Dependent Claim
17 words
The composition of claim 7 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
Claim 13
Dependent Claim
17 words
The composition of claim 7 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
Claim 14
Dependent Claim
36 words
The composition of claim 10 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said composition further comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
Claim 15
Dependent Claim
15 words
The composition of claim 12 wherein said concentration is from about 0.05% to about 0.1%.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-08-03 | 1985-02-02 | 1985-08-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-08-03 | 1989-02-02 | 1989-08-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-08-03 | 1993-02-02 | 1993-08-04 | $7700.00 | Window Closed / Lapsed |